Vancouver, British Columbia – (September 19th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Paramjit Tappia to its scientific advisory team.
Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Tappia into our scientific advisory team. His achievements in scientific and clinical research space will be a major asset to BioMark. Dr. Tappia’s expertise in regulatory and clinical research brings depth and practicality as we begin to commercialize and position our technology for different oncology applications and potential linkages with other leading global institutions.”
“Biological markers are urgently needed to improve early detection, diagnosis and measuring response to treatment for cancers at large. BioMark’s technology platform could be a critically important tool for clinicians and the medical institutions”, says Dr. Tappia.
About Dr. Paramjit Tappia
Dr. Tappia over 30 years of research, including clinical and regulatory experience in clinical research with focus on nutrition in health and disease, developing novel biomarkers for human disease and understanding of subcellular and molecular mechanisms of different pathophysiological conditions. He is currently the Principal Investigator and Clinical Scientist at Asper Clinical Research Institute, St. Boniface Hospital where he manages and facilitates clinical studies for major corporations. Dr. Tappia holds Ph.D. in Biochemistry from University of Wolverhampton, U.K. and has published over 100 peer-reviewed articles in leading journals and 26 book chapter contributions. Dr. Tappia is regularly invited to present at national and international conferences. He is also actively involved in various community services across the province of Manitoba.